A catheter structure capable of controlling the position of drug liquid release

Abstract

The application discloses a catheter structure capable of controlling the releasing position of medicine liquid and belongs to the technical field of catheters. The catheter structure comprises a catheter main body, a plurality of medicine-feeding air bags are arranged on the surface of the catheter main body, a plurality of medicine-feeding holes are arranged on the side of the medicine-feeding air bags facing the outside of the human body, a plurality of medicine-feeding channels matched with the number of the medicine-feeding air bags are arranged in the catheter, one end of the medicine-feeding channels is arranged in the end of the catheter main body in a flush manner and is communicated with the outside, the depth of the other end of the medicine-feeding channels in the catheter main body is respectively corresponding to the position of the medicine-feeding air bags, and the other end is respectively communicated with the medicine-feeding air bags, a medicine-feeding hose is arranged at one end of the medicine-feeding channel on the end of the catheter main body, and one end of the medicine-feeding hose is connected with the end of the medicine-feeding channel. The technical scheme is used to solve the problem that it is difficult to realize accurate medicine feeding in the urethra when medicine liquid is injected into the urethra through the catheter in the prior art.

Description

Technical Field

[0001] This invention belongs to the field of urinary catheter technology, specifically relating to a urinary catheter structure that allows for control of the release position of medication. Background Technology

[0002] Urethral stricture is a common lower urinary tract disease in men. Its causes include perineal injury, iatrogenic injury, and chronic inflammation. The natural course of urethral stricture usually begins with damage and inflammation of the urethral mucosa, followed by abnormal proliferation of extracellular matrix at the site of injury and scar formation, which leads to a reduction in the urethral lumen and difficulty in urination.

[0003] In existing technologies, 5-fluorouracil (5-FU) combined with glucocorticoids can be used to treat urethral scars, but how to inject the drug into the urethra where treatment is needed is a problem that urgently needs to be solved.

[0004] For example, a urethral stricture drug delivery catheter with patent number CN202121157519.2 includes a catheter, a catheter fixing mechanism, a limiting mechanism at the anastomosis of the urethral stricture, a drug delivery mechanism, and a urethral stricture visual balloon dilator. Although this technical solution can inject drugs into the urethra through a catheter, the injection site is fixed, and the position of the catheter after insertion is also relatively fixed. Therefore, the injection site relative to the urethra is also relatively fixed. However, the sites for drug delivery within the length of the urethra are not fixed. Therefore, the prior art can only achieve drug delivery over a large area of ​​the urethra and cannot achieve precise drug delivery to the site in the urethra that needs to be drug delivered through a catheter. Summary of the Invention

[0005] In view of this, the purpose of the present invention is to provide a catheter structure that can control the release position of the drug solution, so as to solve the problem in the prior art that it is difficult to achieve precise drug delivery into the urethra when injecting the drug solution into the urethra through the catheter.

[0006] To achieve the above objectives, the present invention provides the following technical solution:

[0007] This invention discloses a urinary catheter structure with controllable drug release position, comprising a catheter body, a plurality of drug delivery balloons on the surface of the catheter body, a plurality of drug delivery holes on the side of the drug delivery balloons facing the outside of the body, a plurality of drug delivery channels matching the number of drug delivery balloons inside the catheter, one end of each of the drug delivery channels being flush with the end of the catheter body and communicating with the outside, the other end of each of the drug delivery channels being located at a depth inside the catheter body corresponding to the position of each drug delivery balloon, and the other end communicating with each drug delivery balloon, each drug delivery channel having a drug delivery hose at one end of the end of the catheter body, one end of the drug delivery hose being connected to the end of the drug delivery channel, and a constant pressure pump being provided at the other end of the drug delivery channel.

[0008] Furthermore, each of the aforementioned drug delivery tubing is equipped with a first control valve.

[0009] Furthermore, the drug delivery balloon has an annular partition in the middle, which divides the inside of the drug delivery balloon into two independent chambers. The two independent chambers are a drug delivery chamber with a drug delivery port and a blocking chamber without a drug delivery port. One end of the drug delivery channel located inside the main body of the catheter is connected to the drug delivery chamber of the drug delivery balloon at its corresponding position, and is also connected to the blocking chamber of the adjacent drug delivery balloon in the direction of the drug delivery balloon facing the outside of the human body at its corresponding position.

[0010] Furthermore, the catheter body has a drainage channel in the middle, and at least one through drainage hole is provided at one end of the drainage channel inside the human body. A drainage pipe is provided at the other end of the drainage channel, and a second control valve is provided on the drainage pipe.

[0011] Furthermore, the main body of the urinary catheter is provided with an injection channel, and the end of the injection channel located inside the human body is provided with a through injection hole. The main body of the urinary catheter is provided with an inflatable balloon, which is connected to the injection hole. The other end of the injection channel is provided with an injection tube, which is provided with a third control valve. The distance between the inflatable balloon and the end of the urinary catheter main body located inside the human body is less than the distance between any drug delivery balloon and the end of the urinary catheter located inside the human body.

[0012] Furthermore, several of the drug delivery balloons are evenly distributed along the length of the catheter.

[0013] Furthermore, the spacing between adjacent drug delivery airbags is 2-5 cm.

[0014] Furthermore, the inflation height of the drug delivery balloon is 0.3-1 mm.

[0015] Furthermore, several of the described drug delivery tubing are evenly distributed around the edge of one end of the catheter body.

[0016] The beneficial effects of this invention are as follows:

[0017] (1) In this technical solution, the setting of the drug delivery channel and the drug delivery balloon can accurately deliver the drug to the location in the patient's urethra that needs to be delivered, so that the catheter has the function of delivering the drug to the urethra and improves the effect of urethral drug delivery.

[0018] (2) The setting of the annular septum in the drug delivery balloon and the connection method between the drug delivery channel and the adjacent drug delivery balloon can achieve segmented and precise drug delivery to the site in the urethra where the drug needs to be delivered, while also allowing the drug solution injected into the urethra to stay at the site where the drug needs to be delivered for a long time, so that the drug solution can have more sufficient contact with the site in the urethra where the drug needs to be delivered, and further improve the effect of urethral drug delivery.

[0019] Other advantages, objectives, and features of the invention will be set forth in the following description and will be apparent to those skilled in the art in some respects, or may be learned by practice of the invention. The objectives and other advantages of the invention can be realized and obtained through the following description. Attached Figure Description

[0020] To make the objectives, technical solutions, and beneficial effects of this invention clearer, the following figures are provided for illustration:

[0021] Figure 1 This is a three-dimensional schematic diagram of the urinary catheter structure of the present invention;

[0022] Figure 2 This is a schematic cross-sectional view of the drug delivery channel and drug delivery balloon in the urinary catheter structure of the present invention;

[0023] Figure 3 This is a schematic cross-sectional view of the drainage channel and the injection channel in the catheter structure of the present invention;

[0024] Figure 4 For the present invention Figure 2 A magnified view of a portion of point A in the middle;

[0025] Figure 5 For the present invention Figure 3 A magnified view of a portion of point B in the middle.

[0026] The following labels are shown in the attached diagram:

[0027] The catheter consists of: 1. Main body of the catheter; 2. Drainage channel; 3. Drainage hole; 4. Injection channel; 5. Inflatable balloon; 6. Injection tube; 7. Drug administration balloon; 8. Annular septum; 9. Drug administration hole; 10. Drug administration channel; 11. Drug administration tubing; 12. Detailed Implementation

[0028] like Figures 1-5As shown, this invention discloses a urinary catheter structure with controllable drug release position, comprising a catheter body 1. The material of the catheter body 1 is existing technology and will not be described in detail here. Several drug delivery balloons 8 are provided on the surface of the catheter body 1. The drug delivery balloons 8 are positioned on the catheter body 1 in the same way as the inflatable balloons 6 on existing catheters. They adhere tightly to the outer surface of the catheter body 1 without pressure and only inflate when pressure is applied. Several drug delivery holes 10 are provided on the side of the drug delivery balloons 8 facing the outside of the body. The diameter of the drug delivery holes 10 can be designed according to actual conditions. The inside of the catheter has several drug delivery channels 11 matching the number of drug delivery balloons 8. The drug delivery channels 11 are... A blind hole is made on the main body 1 of the urinary catheter, with one end closed and the other end connected to the outside. One end of several drug delivery channels 11 is flush with the end of the main body 1 of the urinary catheter and is connected to the outside. The depth of the other end of the drug delivery channels 11 inside the main body 1 of the urinary catheter corresponds to the position of the drug delivery balloon 8. That is, each drug delivery balloon 8 has a drug delivery channel 11 with its end flush with it inside the main body 1 of the urinary catheter. The end of the drug delivery channel 11 is connected to the drug delivery balloon 8. One end of the drug delivery channel 11 at the end of the main body 1 of the urinary catheter is provided with a drug delivery tube 12. One end of the drug delivery tube 12 is connected to the end of the drug delivery channel 11. A constant pressure pump is provided on the other end of the drug delivery channel 11.

[0029] The principle behind the above technical solution for achieving precise drug injection is as follows:

[0030] Because each drug delivery channel 11 is connected to a drug delivery balloon 8 located at different positions on the main body of the catheter 1, when injecting medication into the urethra, it is only necessary to identify the site in the urethra where the medication needs to be injected. After inserting the catheter, it is then determined which drug delivery channel 11 matches the injection site. The medication is then injected into the drug delivery tubing 12 on that drug delivery channel 11 using a constant pressure pump. The medication will then enter the drug delivery balloon 8 through the drug delivery channel 11, and then seep out through the drug delivery hole 10, flowing onto the inner wall of the urethra to deliver the medication to the site in the urethra where medication is needed. It is easy to understand that since the catheter is essentially in a downward position after insertion, the drug delivery hole 10 is located on the side facing the outside of the body to facilitate the flow of medication from a high to a low position in the urethra, thus covering the entire area of ​​the urethra where medication needs to be administered. Therefore, the drug delivery balloon 8 should be positioned above the site in the urethra where medication needs to be administered. Of course, to further enhance the cumulative effect of the medication in this area, the end of the main body of the catheter located on the outside of the body can be manually raised appropriately.

[0031] In one feasible approach, a first control valve is provided on several administration tubing. The first control valve is designed to control the injection volume of the drug solution and to prevent backflow of the drug solution under the pressure of the urethra, as backflow would cause contamination of the external drug solution. Therefore, the first control valve can be a one-way valve as in the prior art.

[0032] like Figure 4 As shown, in one feasible embodiment, the administration balloon 8 has an annular partition 9 in the middle. The material of the annular partition 9 is the same as that of the balloon. The annular partition 9 divides the interior of the administration balloon 8 into two independent chambers. The two independent chambers are an administration chamber with an administration port 10 and a blocking chamber without an administration port 10. One end of an administration channel 11 located inside the catheter body 1 is connected to the administration chamber of the administration balloon 8 at its corresponding position. At the same time, it is also connected to the blocking chamber of the adjacent administration balloon 8 in the direction of the administration balloon 8 facing the outside of the human body at its corresponding position. In simple terms, an administration channel 11 is connected to an adjacent administration chamber and a blocking chamber respectively.

[0033] The advantages of the above technical solution are that, after confirming the site in the urethra where medication needs to be administered, medication is injected into the corresponding medication tubing 12. Under the pressure of the medication, both the medication chamber and the sealing chamber expand and come into contact with the inner wall of the urethra. Due to the pressure of the patient's urethra, the two chambers can achieve a certain degree of sealing, thus sealing the site in the urethra where medication needs to be administered between the medication chamber and the sealing chamber. When the medication seeps out from the medication port 10 into the urethra, it will be intercepted in the medication chamber and the sealing chamber, and will accumulate in this area (in normal medication, the medication will be directly discharged outward from the inner wall of the urethra). This will soak the inner wall of the urethra in this area, thereby improving the contact and coverage effect between the medication and the site in the urethra where medication needs to be administered. At the same time, this setting method can also perform segmented and precise medication administration to the site in the urethra where medication needs to be administered, reducing the amount of medication used.

[0034] In one feasible embodiment, the catheter body 1 has a drainage channel 2 in the middle. The drainage channel 2 has at least one through drainage hole 3 at one end inside the body. The other end of the drainage channel 2 has a drainage tube 4. The drainage tube 4 has a second control valve, which is a one-way valve in the prior art. The function of the drainage channel 2 is to drain the medicine in the patient's bladder to the outside through the drainage hole 3. The specific working principle will not be elaborated here.

[0035] In one feasible embodiment, the catheter body 1 is provided with an injection channel 5. An injection hole is provided through the end of the injection channel 5 located inside the body. An inflatable balloon 6 is provided on the catheter body 1, communicating with the injection hole. An injection tube 7 is provided at the other end of the injection channel 5, and a third control valve is provided on the injection tube 7. The distance between the inflatable balloon 6 and the end of the catheter body 1 located inside the body is less than the distance between any drug delivery balloon 8 and the end of the catheter located inside the body. Injecting liquid into the injection channel 5 through the injection tube 7 inflates the inflatable balloon 6, causing it to become lodged in the patient's bladder, preventing catheter dislodgement. The specific working principle and structure will not be elaborated further here.

[0036] In one feasible method, a plurality of drug delivery balloons 8 are evenly distributed along the length of the catheter, and the distribution spacing between adjacent drug delivery balloons 8 is 2-5cm, preferably 2cm. It is easy to understand that multiple types of catheters can be set according to the length of the urethra and the length that may need to be drug delivered, such as the distance between adjacent drug delivery balloons 8 being 1cm, 2cm, 5cm and 7cm, etc.

[0037] In one feasible approach, the inflation height of the drug delivery balloon 8 is 0.3-1 mm. The inflation height refers to the distance between the catheter body 1 and the urethra at that location after inflation. The distance should be relatively small while achieving compression closure to avoid excessive compression of the urethra and causing patient discomfort. Preferably, it is 0.5 mm, but it can be set according to the situation.

[0038] In one feasible approach, several administration tubing 12 are evenly distributed around the edge of one end of the catheter body 1, while the injection tube 7 is positioned opposite the administration tubing 12. This avoids the problem of inconvenience caused by overly dense distribution.

[0039] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made to it in form and detail without departing from the scope defined by the claims of the present invention.

Claims

1. A catheter structure with controllable drug release location, characterized in that: The catheter includes a main body, on the surface of which are provided several drug delivery balloons. Each drug delivery balloon has several drug delivery holes on its side facing the outside of the body. The catheter interior has several drug delivery channels matching the number of drug delivery balloons. One end of each drug delivery channel is flush with the end of the catheter main body and communicates with the outside. The other end of each drug delivery channel is located at a depth corresponding to the position of a drug delivery balloon within the catheter main body, and this other end communicates with each drug delivery balloon. Each drug delivery channel has a feeding device at its end on the catheter main body. The catheter has a flexible tube, one end of which is connected to the end of the drug delivery channel, and a constant pressure pump is provided at the other end of the drug delivery channel. The drug delivery balloon has an annular partition in the middle, which divides the inside of the drug delivery balloon into two independent chambers. The two independent chambers are a drug delivery chamber with a drug delivery port and a blocking chamber without a drug delivery port. One end of the drug delivery channel located inside the main body of the catheter is connected to the drug delivery chamber of the drug delivery balloon at its corresponding position, and is also connected to the blocking chamber of the adjacent drug delivery balloon in the direction of the drug delivery balloon facing the outside of the human body at its corresponding position.

2. The catheter structure with controllable drug release position according to claim 1, characterized in that: Each of the aforementioned drug delivery tubing is equipped with a first control valve.

3. The catheter structure with controllable drug release position according to claim 1, characterized in that: The catheter body has a drainage channel in the middle, and at least one through drainage hole is provided at one end of the drainage channel inside the human body. A drainage pipe is provided at the other end of the drainage channel, and a second control valve is provided on the drainage pipe.

4. The catheter structure with controllable drug release position according to claim 1, characterized in that: The catheter body is provided with an injection channel, and an injection hole is provided through the end of the injection channel located inside the human body. The catheter body is provided with an inflatable balloon, which is connected to the injection hole. An injection tube is provided at the other end of the injection channel, and a third control valve is provided on the injection tube. The distance between the inflatable balloon and the end of the catheter body located inside the human body is less than the distance between any drug delivery balloon and the end of the catheter located inside the human body.

5. The catheter structure with controllable drug release position according to claim 1, characterized in that: Several of the aforementioned drug delivery balloons are evenly distributed along the length of the urinary catheter.

6. The catheter structure with controllable drug release position according to claim 5, characterized in that: The spacing between adjacent drug delivery airbags is 2-5 cm.

7. The catheter structure with controllable drug release position according to claim 1, characterized in that: The inflation height of the drug delivery airbag is 0.3-1 mm.

8. The catheter structure with controllable drug release position according to claim 1, characterized in that: Several of the aforementioned drug delivery tubing are evenly distributed around the circumference of one edge of the catheter body.

Images